StockData
Longeveron Inc. logo

Longeveron Inc. (LGVN) stock

LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.92−0.19 (-9.00%)

Close on Nov 18, 2026Market cap $61.21MP/E –Yield –

Longeveron operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Longeveron's operating cash flow for the twelve months ending Jun 30, 2026 was -$20.37M. For fiscal 2025 it was -$18.65M. The highest annual figure on record is -$2.36M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$18.65M–
FY2024Dec 31, 2024-$13.87M–
FY2023Dec 31, 2023-$19.00M–
FY2022Dec 31, 2022-$13.97M–
FY2021Dec 31, 2021-$9.64M–
FY2020Dec 31, 2020-$2.36M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.65M–
Q1 FY2026Mar 31, 2026-$4.37M–
Q4 FY2025Dec 31, 2025-$5.30M–
Q3 FY2025Sep 30, 2025-$5.06M–
Q2 FY2025Jun 30, 2025-$3.60M–
Q1 FY2025Mar 31, 2025-$4.70M–
Q4 FY2024Dec 31, 2024-$3.37M–
Q3 FY2024Sep 30, 2024-$2.84M–
Q2 FY2024Jun 30, 2024-$4.57M–
Q1 FY2024Mar 31, 2024-$3.09M–
Q4 FY2023Dec 31, 2023-$4.00M–
Q3 FY2023Sep 30, 2023-$4.56M–
Q2 FY2023Jun 30, 2023-$4.60M–
Q1 FY2023Mar 31, 2023-$5.85M–
Q2 FY2022Jun 30, 2022-$3.28M–
Q1 FY2022Mar 31, 2022-$4.15M–
Q4 FY2021Dec 31, 2021-$1.28M–
Q3 FY2021Sep 30, 2021-$2.37M–
Q2 FY2021Jun 30, 2021-$2.95M–
Q1 FY2021Mar 31, 2021-$3.03M–
Q4 FY2020Dec 31, 2020-$505.00K–
Q3 FY2020Sep 30, 2020-$233.00K–
Q2 FY2020Jun 30, 2020-$1.23M–
Q1 FY2020Mar 31, 2020-$398.00K–

More Longeveron figures

See a number that looks wrong?